Lymphocytapheresis in the treatment of psoriasis vulgaris

Journal of Clinical Apheresis

Volumn 21, Issue 3, 2006, Pages 158-164

  Liumbruno, Giancarlo Maria ^a   Centoni, Paolo Emilio ^a   Molfettini, Pietra ^a   Ceretelli, Silvia ^a   Ceccarini, Massimo ^a   Bachini, Laura ^a   Pomponi, Adriano ^a   Bagnoni, Giovanni ^a   Vitolo, Margherita ^a   Eberle, Olimpia ^a   Biondi, Alessandro ^a   Sodini, Maria Laura ^a  

^a Livorno Hospital   (Italy)

Author keywords

Apheresis; Autoimmune skin disease; Cytapheresis; Lymphocyte depletion; PASI

Indexed keywords

ADULT; APHERESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTAPHERESIS; DISEASE SEVERITY; FEMALE; HUMAN; LEUKAPHERESIS; LEUKOCYTE; MALE; PSORIASIS VULGARIS; SCORING SYSTEM; ADSORPTION; AUTOIMMUNE DISEASE; CASE REPORT; CYTOLOGY; GRANULOCYTE; INFLAMMATION; LYMPHOCYTE; METABOLISM; METHODOLOGY; MIDDLE AGED; MONOCYTE; PATHOLOGY; PSORIASIS; SKIN;

ADSORPTION; ADULT; AUTOIMMUNE DISEASES; BLOOD COMPONENT REMOVAL; FEMALE; GRANULOCYTES; HUMANS; INFLAMMATION; LEUKAPHERESIS; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; PSORIASIS; SKIN;

EID: 34147219956     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20079     Document Type: Article

References (21)

1. Villadsen LS, Schuurman J, Beurskens F, Dam TM, Dagnæs-Hansen F, Skov L, Rygaard J, Voorhorst-Ogink MM, Gerritsen AF, van Dijk MA, Parren PWHI, Baadsgaard O, van de Winkel JGJ. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003;112:1571-1580.
2. Gudjonsson JE, Johnston A, Sigmundstottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004;135:1-8.
3. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996;98:1878-1887.
4. Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatol Treat 2004;15:27-29.
5. Feldman SR, Krueger GC. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64(Suppl II):ii65-ii68.
6. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50:859-866.
7. Clemmensen OJ, Andresen R, Andersen E. Plasmapheresis in the treatment of psoriasis. A controlled clinical study. J Am Acad Dermatol 1983;8:190-192.
8. Guillot B. Extracorporeal systems for the treatment of psoriasis. Plasma Ther Transfus Technol 1987;8:143-146.
9. Wilfert H, Honigsmann H, Steiner G, Smolen J, Wolff K. Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol 1990;122:225-232.
10. Vonderheid EC, Kang CA, Kadin M, Bigler RD, Griffin TD, Rogers TJ. Extracorporeal photopheresis in psoriasis vulgaris: clinical and immunological observation. J Am Acad Dermatol 1990;23:703-712.
11. de Misa RF, Azana JM, Harto A, Ledo A. Extracorporeal photochemotherapy in the treatment of severe psoriatic arthropaty. Br J Dermatol 1992;127:448.
12. de Misa RF, Azana JM, Harto A, Boixede P, Morena R, Ledo A. Psoriatic arthritis: one year of treatment with extracorporeal photochemotherapy. J Am Acad Dermatol 1994;30:1037-1038.
13. Vahlquist C, Larsson M, Ernerudh J, Berlin G, Skogh T, Vahlquist A. Treatment of psoriatic arthritis with extracorporeal potochemotherapy and conventional psoralen-ultraviolet A irradiation. Arthritis Rheum 1996;39:1519-1523.
14. Kanekura T, Yoshii N, Yonezawa T, Kanzaki T. Treatment of pustular psoriasis with granulocyte and monocyte adsorption apheresis. J Am Acad Dermatol 2003;49:329-332.
15. Kanekura T, Kawabata H, Maruyama I, et al. Treatment of psoriatic arthritis with granulocyte and monocyte adsorption apheresis. J Am Acad Dermatol 2004;50:242-246.
16. Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm 2004;10:318-325.
17. Naldi L, Svensson A, Diepgen T, Elsner P, Grob JJ, Counraads PJ, Bavink JN, Williams M, European Dermato Epidemiology Network. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003;120:738-741.
18. Gordon KB, McCormick TS. Evolution of biologic therapies for the treatment of psoriasis. Skinmed 2003;2:286-294.
19. Yamaji K, Tsuda H, Hashimoto H. Current topics on cytapheresis technologies. Ther Apher 2001;5:287-292.
20. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999;41:581-583.
21. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatol Treat 2004; 15:280-294.